Related Experiment Video

Updated: May 24, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Plasminogen activator inhibitor-1 and angiotensin converting enzyme gene polymorphisms in Turkish asthmatic children

E Bora1, R Soylar2, Z Arıkan-Ayyıldız3

  • 1Dokuz Eylul University, Faculty of Medicine, Department of Medical Genetics, Balçova, İzmir, Turkey.

Allergologia Et Immunopathologia
|February 25, 2012
PubMed

Insights

The plasminogen activator inhibitor-1 (PAI-1) 4G allele may increase the risk of childhood asthma. However, angiotensin-converting enzyme (ACE) gene polymorphisms are not associated with childhood asthma in Turkish children.

Area of Science:

  • Genetics
  • Pediatrics
  • Immunology

Background:

  • Genetic polymorphisms in plasminogen activator inhibitor-1 (PAI-1) and angiotensin-converting enzyme (ACE) are linked to asthma susceptibility.
  • Investigating the genetic basis of childhood asthma is crucial for understanding disease development.

Purpose of the Study:

  • To determine the association between childhood asthma and polymorphisms in the PAI-1 and ACE genes.
  • To explore potential genetic risk factors for asthma in a Turkish pediatric population.

Main Methods:

  • A case-control study involving 102 asthmatic children and 101 healthy controls (ages 5-15).
  • Analysis of PAI-1 4G/5G and ACE I/D gene polymorphisms using polymerase chain reaction.
  • Asthmatic children were stratified based on family history of atopy.

Main Results:

  • The PAI-1 4G allele was significantly more prevalent in asthmatic children than in controls (p<0.05).
  • No significant association was found between ACE I/D genotypes and childhood asthma.
  • No significant correlations were observed between these gene polymorphisms and total serum IgE or skin prick test results.

Conclusions:

  • The PAI-1 4G allele may represent a genetic risk factor for childhood asthma.
  • ACE gene I/D polymorphisms do not appear to contribute to asthma development in this cohort of Turkish children.
Abstract

Keywords:
ACEAsthmaChildrenPAI-1Polymorphisms

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms: